Catalyst Brief

← Calendar

Readoutin 75d

Innovent Biologics (Suzhou) Co. Ltd. — Aflibercept Ophthalmic

Phase 3 primary completion: A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD.

Date
Feb 2027
Type
Readout
Indication
Neovascular Age-related Macular Degeneration

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Innovent Biologics (Suzhou) Co. Ltd.

  1. Dec2026
  2. Dec2026